Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol and Temozolomide in Recurrent Glioblastoma
NCT06218524Phase 2Not yet recruiting
- Sponsor
- Southern Medical University
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of haloperidol in glioblastoma (GBM) (2 arms), sponsored by Southern Medical University. Primary endpoint: Objective Response Rate at 3 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
haloperidol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06218524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218524.